Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus

NCT04970719 is registered in ClinicalTrials.gov with Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders as lead sponsor.

NCT NCT04970719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04970719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus
Lead sponsor
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Phase
Phase 3
Overall status
Withdrawn
Start date
July 10, 2021
Completion date
December 31, 2021
Enrollment
0 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia